High-Throughput Screening (HTS) Market valued at US$25.7 billion in 2023, is forecasted to grow at a robust CAGR of 11.8%, reaching US$28.8 billion in 2024 and an impressive US$50.2 billion by 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
There has been a substantial increase in the R&D funding which is supporting the innovation efforts for the development of novel therapeutics. Therefore, increasing drug discovery initiatives are leading to the growing adoption of high throughput screening (HTS) offerings and technologies. However, the high costs associated with the HTS instruments are anticipated to hinder market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950
Browse in-depth TOC on "High-Throughput Screening (HTS) Market"
471 - Tables
49 - Figures
373 - Pages
The consumables segment accounted for the largest share, by application in the high-throughput screening (HTS) market in 2022.
On the basis type of product & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software. In 2022, consumables accounted for the largest share of the high-throughput screening market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research.
The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening (HTS) market in 2022.
Based on application, the high-throughput screening market is categorized into drug discovery, biochemical screening, life sciences research, and other applications. The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2022. The key factor driving this segment's growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.
North America was the largest regional market for high-throughput screening in 2022.
Geographically, the high-throughput screening market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In 2022, North America accounted for the largest share of the high-throughput screening market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the increasing prevalence of diseases, rising pharmaceutical R&D expenditure, and the presence of major players in the region are factors driving the growth of the HTS market in this region.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950
High-Throughput Screening (HTS) Market Dynamics:
Drivers:
- The growing adoption of open innovation models in pharmaceutical & biotechnology companies
- Government funding and venture capital investments
- Increasing R&D spending
- Technological advancements in the HTS market
Restraints:
- The capital-intensive nature of HTS instruments
- Complexities in assay development
Opportunities:
- Emerging markets
- Growing applications in stem cell research
Challenges:
- The dearth of skilled operators
Key Market Players:
Key players in the high-throughput screening (HTS) market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Trading AG (Switzerland), AXXAM S.p.A (Italy), Promega Corporation (US), Bio-Rad Laboratories, Inc.(US), Promega Corporation (US), Hamilton Company (US), Corning Incorporated (US), Charles River Laboratories (US), Lonza (Switzerland), REPROCELL Inc. (Japan), Aurora Biomed (Canada), BMG LABTECH (Germany), DIANA Biotechnologies, s.r.o. (Czech Republic), NanoTemper Technologies GmbH (Germany), Creative Biolabs (US), Biomat Srl (Italy), HighRes Biosolutions (US), Cyclica Inc. (Canada), Crown Bioscience (US), and Sygnature Discovery (UK).
Recent Developments:
- In February 2023, Agilent Technologies, Inc. launched the on-deck thermal cycler that integrates with the Agilent Bravo NGS automated liquid handling platform.
- In February 2023, PerkinElmer Inc. launched the Multimode Plate Reader for high-throughput screening (HTS) applications and to accelerate drug discovery efforts.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950
High-Throughput Screening (HTS) Market Advantages:
- Accelerated Drug Discovery: High-throughput screening (HTS) expedites the drug discovery process by quickly screening a large number of compounds against specific targets. This speed enables researchers to identify potential drug candidates more rapidly, reducing the time and resources required for drug development.
- Increased Efficiency: HTS employs automation, robotics, and advanced technologies, resulting in enhanced efficiency and productivity. The automated systems can handle multiple samples simultaneously, reducing manual labor and minimizing human error. This streamlines the screening process, allowing researchers to screen thousands or even millions of compounds in a shorter time frame.
- Comprehensive Screening: HTS offers a systematic and comprehensive approach to screening compounds. By screening a vast library of compounds, including diverse chemical structures and natural products, HTS increases the likelihood of identifying compounds with desired biological activities. This broad exploration expands the possibilities for discovering novel drug candidates.
- Target-specific Screening: HTS enables researchers to target specific molecular pathways or cellular functions, allowing for more focused screening. This approach increases the chances of identifying compounds that interact with the desired targets, leading to the discovery of potential therapeutics with specific mechanisms of action.
- Cost-effectiveness: Although the initial setup costs of HTS can be significant, the long-term benefits often outweigh the investment. By streamlining the drug discovery process, HTS reduces costs associated with labor, reagents, and time. This cost-effectiveness makes HTS an attractive option for pharmaceutical companies and research institutions aiming to optimize their resources.
- Innovation and Exploration: HTS fosters innovation by enabling researchers to explore vast chemical libraries and screen for various therapeutic targets. This approach encourages the discovery of new drug classes and expands the possibilities for developing treatments for challenging diseases.
- Translational Research: HTS facilitates the translation of basic research findings into practical applications. By efficiently identifying potential drug candidates, HTS bridges the gap between academic research and clinical development, paving the way for the development of new treatments and therapies.
- Beyond Pharmaceutical Applications: HTS has expanded beyond traditional drug discovery and found applications in other fields such as personalized medicine and agricultural research. In personalized medicine, HTS allows for the screening of patient samples to identify tailored treatment options. In agriculture, HTS enables the screening of compounds for crop improvement and disease resistance, optimizing agricultural practices.
In summary, the advantages of the HTS market lie in its ability to accelerate drug discovery, increase efficiency, facilitate comprehensive and targeted screening, offer cost-effectiveness, drive innovation, support translational research, and extend its applications beyond pharmaceuticals. These advantages position HTS as a valuable tool for advancing scientific research and improving human health.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html
https://www.marketsandmarkets.com/PressReleases/high-throughput-screening.asp
Comments
0 comment